We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
PRRC2B
HPA
RESOURCES
  • TISSUE
  • BRAIN
  • SINGLE CELL
  • SUBCELLULAR
  • CANCER
  • BLOOD
  • CELL LINE
  • STRUCTURE & INTERACTION
ABOUT
  • INTRODUCTION
  • HISTORY
  • ORGANIZATION
  • PUBLICATIONS
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • ACKNOWLEDGMENTS
  • CONTACT
NEWS
  • NEWS ARTICLES
  • PRESS ROOM
LEARN
  • DICTIONARY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
  • METHODS
  • EDUCATIONAL VIDEOS
DATA
  • DOWNLOADABLE DATA
  • PUBLICATION DATA
  • RELEASE HISTORY
HELP
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • HELP & FAQ
  • PRIVACY STATEMENT
  • LICENCE & CITATION
Fields »
Search result

Field
Term
Gene name
Class
Subclass
Class
Keyword
Chromosome
External id
Tissue
Cell type
Expression
Antibody panel
Tissue
Main location
Patient ID
Annotation
Tissue
Category
Tau score
Cluster
Reliability
Brain region
Category
Tau score
Brain region
Category
Tau score
Brain region
Category
Tau score
Cluster
Reliability
Tissue
Cell type
Enrichment
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell lineage
Category
Tau score
Cluster
Cluster
Location
Searches
Location
Cell line
Class
Type
Phase
Reliability
Cancer
Prognosis
Cancer
Category
Cancer
Category
Tau score
Cluster
Variants
Interacting gene (ensg_id)
Type
Number of interactions
Pathway
Category
Score
Score
Score
Validation
Validation
Validation
Validation
Antibodies
Data type
Column


  • SUMMARY

  • TISSUE

  • BRAIN

  • SINGLE CELL

  • SUBCELL

  • CANCER

  • BLOOD

  • CELL LINE

  • STRUCT & INT

  • PRRC2B
CANCER COLORECTAL CANCER Show tissue menu
BREAST CANCER CARCINOID CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER GLIOMA HEAD AND NECK CANCER LIVER CANCER LUNG CANCER LYMPHOMA
MELANOMA OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RENAL CANCER SKIN CANCER STOMACH CANCER TESTIS CANCER THYROID CANCER UROTHELIAL CANCER
COAD TCGA COAD VALIDATION READ TCGA READ VALIDATION PROTEIN COAD CPTAC PROTEIN EXPRESSION
ANTIBODIES
AND
VALIDATION
Dictionary
Colorectal cancer
Human cancer
Colon adenocarcinoma
Rectum adenocarcinoma
COLON ADENOCARCINOMA (TCGA) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

  Survival analysis data not available.
COLON ADENOCARCINOMA (VALIDATION) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

  Survival analysis data not available.
RECTUM ADENOCARCINOMA (TCGA) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

  Survival analysis data not available.
RECTUM ADENOCARCINOMA (VALIDATION) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

  Survival analysis data not available.
COLON ADENOCARCINOMA - Protein relative expression (CPTAC)
Number of samples 197
Samples
Sample ID Sample type nRPX
79097be1-cd36-4a23-99d1-3d744f_D2 Tumor 1.5
c6ae57a7-65a0-438e-bae2-97b1c8_D3 Tumor 0.9
c1b66358-d103-493c-b8ec-92c43b_D1 Tumor 0.8
c7aeb685-31b3-445e-8177-a3e729_D3 Tumor 0.7
b4dd4a04-5eda-43dd-8298-215b07_D3 Tumor 0.6
8c73f3a5-fea8-4942-90c0-966f66_D3 Tumor 0.6
642fc6c3-8d4a-4e3d-ad0a-cc088a_D2 Tumor 0.6
f635496c-0046-4ecd-89bc-7a4f33_D2 Tumor 0.5
aa0f5b40-3290-4255-8f4d-f45d4e_D3 Tumor 0.5
903d5fe0-970a-47be-a97f-3cc914_D2 Normal 0.5
01d1ffca-4235-4dfe-bf62-56f71d_D3 Tumor 0.5
f6173181-0993-4a5f-a4cd-5f30b1_D2 Tumor 0.5
5a3aa99d-ca10-45f6-939f-12392a_D2 Normal 0.5
b4e91300-405e-4239-b8da-5e1a42_D2 Tumor 0.5
ec9afcc4-ccf7-4226-b0e8-d6897d_D3 Tumor 0.4
d6584b4a-ca99-4a2a-8b4e-c8b22e_D3 Tumor 0.4
41ee934e-f7a3-4ef5-8a83-e2ac56_D2 Tumor 0.4
ea6df59d-5240-4927-b19d-d44590_D2 Tumor 0.4
21cab01c-e968-42cc-9651-1e53c0_D3 Tumor 0.4
5da00abd-5fa7-4deb-95f1-7982e0_D3 Tumor 0.4
2b810478-7956-4a8b-870d-184859_D2 Tumor 0.3
dffcac99-9eac-4717-aeb6-f4a2e7_D8 Tumor 0.3
bc574f73-89ba-44d7-992e-82622c_D3 Tumor 0.3
e196a0b4-2a05-43de-bb30-ceb761_D2 Tumor 0.3
9bf309bc-0fb6-4060-aba2-888eb3_D2 Tumor 0.3
98742d96-cc2f-43f0-9de2-bc7afe_D3 Tumor 0.3
92f7419c-c57a-4b50-bdc9-4d09ca_D2 Tumor 0.2
176d1b96-8c6e-44fe-8a32-e15194_D2 Normal 0.2
695b0b00-a86b-43c0-a6c8-50a840_D3 Tumor 0.2
f6afe41c-111d-4818-8485-fe95e0_D2 Tumor 0.2
799893aa-d523-4a08-9ea7-611cca_D3 Tumor 0.2
0f757044-9bc8-4ed4-90f3-e0a49a_D3 Tumor 0.2
0aef1fe8-ca61-4113-81d0-d82ee7_D2 Tumor 0.2
e74089a9-f78c-4ffe-8174-aef71b_D2 Normal 0.2
66b829db-1cdd-460d-b2f3-0e9ca9_D3 Tumor 0.2
e2e83b72-b14b-4b06-9461-1115d6_D2 Tumor 0.2
b605fafc-f7dd-44cc-9c86-da04e3_D2 Tumor 0.2
2666323d-522f-4f0a-823c-ff8866_D2 Normal 0.2
d0511ea6-43c3-4c61-b08e-cf49b7_D3 Tumor 0.2
1425a1a1-c835-47a2-a9b9-4db5d0_D8 Tumor 0.2
2f8b02e4-1848-4abc-a95e-dd9eb5_D3 Tumor 0.2
e8faa3a7-9fc7-428e-9334-a0afd0_D3 Tumor 0.2
4bb08fad-fa5e-471e-978b-6b09ab_D2 Tumor 0.2
526c3664-5b9b-4a2b-a00e-a14623_D2 Tumor 0.2
853ecf90-71e6-4156-a56f-a34b65_D2 Normal 0.2
5271982c-5de1-4d6e-b414-b1f3ef_D2 Tumor 0.2
803736b3-9ca9-4f9f-bdfe-8783e3_D3 Tumor 0.2
5f823547-ee16-45b7-a6a0-ef25d6_D3 Tumor 0.2
cfb4831f-e9ee-4e11-80fb-958f6f_D2 Tumor 0.1
c9730cb4-b52c-4ca8-9652-4509d0_D2 Tumor 0.1
37219a7c-6fe2-4684-a494-d0be08_D2 Tumor 0.1
2167c594-c33f-4795-b95b-69bd07_D2 Tumor 0.1
66b57abc-0d49-46bb-a390-0e11a9_D2 Tumor 0.1
8960a27e-69d8-4ec8-a795-c6cf8a_D3 Tumor 0.1
0f238226-864c-4de0-8c61-01e729_D2 Tumor 0.1
2cc46aec-6142-4fb9-aca5-c442b9_D2 Normal 0.1
04ded2cd-3b57-4aec-9c11-48f58e_D2 Normal 0.1
1fbb1add-4660-4ec1-b8c2-360f9f_D2 Normal 0.1
321fb3b2-ebb6-4ea5-b737-081264_D2 Tumor 0.1
b6b41ba2-6415-41aa-b5f5-4d47db_D2 Normal 0.1
0630ecb0-b664-4e75-bb3c-fb62ee_D3 Tumor 0.0
3765c09a-fff7-4b37-bf2b-452b23_D2 Normal 0.0
c65afd57-530c-4366-b2c8-463a46_D2 Tumor 0.0
377cdd37-d1bd-4042-997e-478a0f_D2 Normal 0.0
4cdeecb5-19fb-493c-91f5-eb0efc_D3 Tumor 0.0
b871c0c1-a97b-4ac1-887c-0317b6_D2 Normal 0.0
cd89ffbb-574a-4052-bd9a-00c890_D2 Tumor 0.0
9a6879b1-4f78-4ac6-9fca-dad049_D2 Normal 0.0
efee6bb9-69dd-46c2-85b3-b55962_D2 Normal 0.0
2d266d2d-4bb3-436c-a3e7-06acb2_D3 Tumor 0.0
c8694e31-2c8f-4eb6-a7ef-a137d9_D3 Tumor 0.0
8cc7e656-0152-4359-8566-0581c3 Tumor 0.0
bd67de01-ad7d-431a-9ad6-4dd5a1 Tumor 0.0
e14c2cbe-eca0-4745-97f6-8f27bd_D2 Normal 0.0
a2f03d85-5f1a-4b3e-9dbf-74e67e_D3 Tumor 0.0
7478980a-60fb-4f5e-aa1c-2d7941_D2 Normal 0.0
f5ed5ebc-881d-456a-80d7-42c9e7_D2 Normal 0.0
a5c8bf1d-776c-406f-82a3-2d9ce6_D2 Normal 0.0
e3c012aa-51c2-42b0-a478-bd620f_D2 Normal 0.0
42216d99-e8ff-43c9-b6db-28c3a6_D3 Tumor 0.0
cd6a4013-2958-44b9-a4f1-45c9e4_D2 Tumor 0.0
092c5a37-325b-4181-b230-2d8fff_D2 Tumor 0.0
7cc7f69f-99f5-4b23-a9e0-ba0dc8_D8 Tumor 0.0
019cd0c0-733d-4b25-90e3-d54ce0_D2 Normal 0.0
f4bccfe4-98d0-466b-a6d7-44341b_D3 Tumor -0.1
43192517-085e-450e-9481-0a6713_D3 Tumor -0.1
4b263734-430f-41dc-a296-8691f0_D3 Tumor -0.1
c2c53076-b5db-4b7d-983c-a35740_D3 Tumor -0.1
a467b905-fc0b-427b-8753-6d38dd_D3 Tumor -0.1
206f3bd9-f62c-4663-8fdb-5b731b_D2 Normal -0.1
58a92726-4d1f-4e44-8938-52b97d_D3 Tumor -0.1
f69deaeb-6b6f-4c61-8900-fd0f26_D3 Tumor -0.1
515040a4-bbfb-4a15-9e53-e7b6e6_D2 Normal -0.1
3a17283c-a0f4-4514-956b-080d11_D2 Normal -0.1
47d2a435-b203-4438-ae72-53c424_D2 Normal -0.1
325b5314-6f3c-4d79-9b36-4e7ded_D2 Normal -0.1
5557e478-3e6f-475b-8acc-1b4159_D8 Tumor -0.1
bed27f66-ef3b-4868-b4ad-205018_D2 Normal -0.1
d7608884-a0d6-4e9e-aac7-6cd813_D3 Tumor -0.1
54565eae-05c5-4dae-bde9-ae4874_D2 Normal -0.1
cbd0e774-c741-4753-9c9e-391a7d_D2 Normal -0.1
6e20c8e9-ab75-4996-9296-445b00_D2 Tumor -0.1
46dfc1e4-0110-4d9f-888e-6a29ab_D2 Normal -0.1
87b0e853-43ea-4efb-8a22-dd221f_D2 Normal -0.1
211cbcef-cb1f-4c80-a1c8-a76d3c_D2 Normal -0.1
51590333-cfe5-4ce5-b8ff-58fa3c_D2 Normal -0.2
5cf5e61d-21ff-4678-9126-14e9bb_D2 Normal -0.2
da747cee-5026-4923-af63-ad9f81_D2 Normal -0.2
05a33362-82bb-48ac-8feb-ad2ea1_D2 Tumor -0.2
3d797911-d476-436f-9cce-33e20c_D8 Tumor -0.2
26acb513-3ffe-49ad-8581-9dfc97_D2 Normal -0.2
d80408d6-598d-4411-ab34-eb2545_D2 Normal -0.2
e0068ac5-f557-443a-bd4b-bdfcef_D3 Tumor -0.2
a243b765-61ab-4aa6-88e1-226896_D2 Normal -0.2
92c1ebb5-ac1d-4bf5-a14f-516e1d_D3 Tumor -0.2
1ab06c24-ffc0-4323-a0cc-e9f5c5_D2 Tumor -0.2
b2978e90-cd2a-4665-b1bf-508a99_D2 Normal -0.2
067db520-1b1f-4569-9414-e37a6e_D2 Normal -0.2
62627b73-1763-48bc-8eea-e5bd76_D2 Normal -0.2
76498650-fdbf-4f5d-a19a-cce9a2_D2 Normal -0.3
cd3a9d59-bf13-48f3-ae97-bdbca4_D2 Normal -0.3
0065bfd9-e1b9-43a8-9379-9658ba_D3 Tumor -0.3
7784e2e5-c0e1-4b85-8cc1-7faac8_D2 Normal -0.3
5de06adb-e00d-4114-8d76-04bd30_D2 Normal -0.3
6b0a3188-d8ca-4d50-a377-a8fe4c_D2 Normal -0.3
6e0d04fc-e6a8-41ed-b6f3-45537d_D2 Normal -0.3
5c70e654-583c-4dd3-ad42-0d9b39_D2 Normal -0.3
e1cd3d70-132b-452f-ba10-026721_D2 Tumor -0.3
8fab37a4-cdf9-4ce8-9081-7b9148_D2 Normal -0.3
dfdf03a6-c324-4d8c-a909-ea7345_D2 Tumor -0.3
23e938d0-92b8-4aea-90c1-4385df_D2 Normal -0.3
fc9b09af-23b8-4ffe-b6c6-41236d_D2 Normal -0.3
db3f5ad9-d14d-4126-a3e7-d80faa_D3 Tumor -0.3
233ec093-9a30-4ef4-a12c-91757e_D2 Normal -0.3
1c070992-647b-4173-a481-904c4d_D2 Normal -0.4
1136008b-97ce-49b0-bf24-abbea6_D2 Normal -0.4
722378ea-d1a7-4cfc-aca5-ba45f9_D8 Tumor -0.4
1bf00d93-240f-47e8-8055-f546b0_D2 Normal -0.4
359f5c81-2575-497e-8630-e4866f_D2 Normal -0.4
8af80ae9-2088-4124-91fb-8d6c17_D3 Tumor -0.4
41a04113-2061-4923-bca5-da586c_D2 Normal -0.4
5e886f1c-8165-4232-9591-d80799_D2 Normal -0.4
a313f6ef-5994-4d49-9e66-c26911_D2 Normal -0.4
1f79fed9-f0d4-4c45-acd2-ea1441_D2 Normal -0.4
963fc8db-f412-4427-a198-23f660_D2 Normal -0.4
8980bb9d-65c1-41cb-9f90-dddd5f_D2 Normal -0.4
d8805fa4-30f9-4417-907e-fdc50c_D2 Normal -0.4
43bc845e-d22e-4c10-b3e8-bc54e6_D2 Normal -0.4
c9f0f144-47f3-4d64-b29f-bcedfa_D2 Normal -0.4
da95f6f8-be46-4ed8-a493-2c99f0_D2 Normal -0.5
b3696374-c6c0-49dd-833e-596e26_D2 Normal -0.5
87408d9e-4029-4e8f-b14c-8efc04_D3 Tumor -0.5
694e8df1-d9ee-473b-bec1-4f9237_D2 Normal -0.5
0d5554d1-1653-4589-a44f-43113e_D2 Normal -0.5
d3078fa8-0692-411f-8441-0c7c48_D8 Tumor -0.5
154115ac-2ec2-439d-b55e-0464ee_D2 Normal -0.5
e070ff10-058b-4733-93ab-bdd702_D2 Normal -0.5
65867ab1-5eab-44a8-b2bb-d27263_D2 Normal -0.5
16ac8458-5200-4302-9ad0-b311df_D2 Normal -0.5
a84149b1-8453-45f0-8400-d7b12f_D2 Normal -0.5
4c9dcc8c-ccdc-4336-8e23-107feb_D2 Normal -0.5
df479b07-bbf6-472d-a580-c3fd0c_D2 Normal -0.5
9a48cf57-e1f0-4ea1-9804-d563f2_D2 Normal -0.5
591fb460-703a-437d-8d9a-ff2a35_D3 Tumor -0.5
7bdfa5c9-d11f-4600-9c44-a87996_D2 Normal -0.5
411d9597-c785-4de5-b449-29a80d_D2 Normal -0.5
c307b7b0-534a-45fa-a420-35f773_D2 Normal -0.5
f9d6fb1b-988e-4D88-9272-cc672f_D8 Tumor -0.5
5347d2ce-df0c-4d81-a3e2-22db11_D2 Normal -0.5
bda3787a-1397-4716-bb17-4992a8_D2 Normal -0.5
6d9f8b06-f28c-4e9b-823b-33ebb7_D2 Normal -0.5
573048dd-2502-40e0-8e8c-c41bb8_D3 Tumor -0.5
372c900a-fced-4eef-9dc4-7282ec_D2 Tumor -0.5
6797a69d-2f74-44b9-8147-cd4fac_D2 Normal -0.6
1563ef63-d2e6-406f-adc1-255949_D3 Tumor -0.6
0c330883-ab58-4a5a-bff7-07d283_D2 Normal -0.7
88c621d7-7fb3-4825-abbe-82ae4c_D2 Normal -0.7
820a3f08-5bb1-44b3-a133-ee167e_D2 Tumor -0.7
64ed43a2-f083-43cb-9d0d-118495_D2 Normal -0.7
b2400046-1d25-429d-a821-6040a6 Tumor -0.7
63c1f7ac-b1ae-4c28-95aa-ce21e5_D2 Normal -0.8
3e8019e8-125f-4615-a1fa-a448e9_D2 Normal -0.8
02cde0c0-6840-495b-9b11-007d82_D2 Normal -1.0
e515eb5c-8005-416a-9b42-59de9d_D8 Tumor -1.0
cc271b3d-ed33-481f-9d23-15f2f6_D2 Normal -1.1
0784c7b3-e6a4-42a8-9288-eb4ba0_D2 Normal -1.1
348f6009-e1be-44d2-a093-9ca844_D2 Normal -1.3
82157a70-12f1-4913-b548-d98881_D2 Normal -1.3
a90eb718-6a8f-4cbf-89c1-f9e9bd_D2 Tumor N/A
8b9e4266-7754-4f2c-ac9e-329905_D2 Tumor N/A
7fd386f0-e7f6-4ee1-9cd7-b3318a_D2 Normal N/A
f6b1079b-9d67-4c63-b3d0-d562b5_D2 Tumor N/A
71b2c1cc-0a31-4ca8-8beb-251e17_D2 Normal N/A
974e136f-7020-4a38-b9c1-094df9_D2 Normal N/A
a27cf22d-836e-49a7-802f-47c1db_D2 Normal N/A
7fd2eea8-bf99-4f97-8b9e-fb703f_D2 Normal N/A
059a7065-3a5f-4eea-97e5-85ab01_D2 Normal N/A
Show allShow less
COLORECTAL CANCER - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

Antibody stainingi

Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.

Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.


Antibody HPA021022
 Staining
  High
  Medium
  Low
  Not detected
 Intensity
  Strong
  Moderate
  Weak
  Negative
 Quantity
  >75%
  75%-25%
  <25%
  None
 Location
  Nuclear
  Cytoplasmic/membranous
  Cytoplasmic/membranous,nuclear
  None
Adenocarcinoma, NOS

Contact

  • NEWS ARTICLES
  • PRESS ROOM

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS

The Human Protein Atlas

  • DOWNLOADABLE DATA
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.


contact@proteinatlas.org